This study is for young patients with a type of blood cancer called acute myeloid leukemia (AML). Doctors are testing different drug combinations to see which works best. The drugs include:
- Cytarabine and Daunorubicin: These drugs can stop cancer cells from growing by interfering with DNA, the material in cells that carries genetic information.
- Venetoclax: This medicine blocks a protein that helps cancer cells survive.
- Azacitidine: This drug activates genes that fight tumors, helping to stop cancer growth.
The study goal is to find out if adding venetoclax to the treatment makes it more effective. Patients are divided into three groups, each getting a different treatment combination. Doctors will check the cancer's response through blood and bone marrow tests. The study lasts for 2 years.
- Key Points:
- Participation requires regular hospital visits for treatment and testing.
- Potential side effects from the drugs will be monitored.
- Participants must be between 18-59 years old and meet specific health criteria.
How understandable was the trial content above?
Hard to understand
Easy to understand